Stanley Druckenmiller
XENE icon

Stanley Druckenmiller’s Xenon Pharmaceuticals XENE Stock Holding History

Stanley Druckenmiller’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Hold
238,600
– – 0.28% 68
2026
Q1 		$13.9M Buy
+238,600
New +$11M 0.41% 50

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Stanley Druckenmiller's XENE Position: Q2 2026 in Review

Stanley Druckenmiller held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 238,600 shares worth $14.4M. The position accounts for 0.28% of the portfolio, ranked #68.

Stanley Druckenmiller first reported a position in XENE in Q1 2026 and has held it in 2 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Stanley Druckenmiller held 238,600 shares of Xenon Pharmaceuticals worth $14.4M as of Q2 2026.
  • Stanley Druckenmiller left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
  • Xenon Pharmaceuticals made up 0.28% of Stanley Druckenmiller's portfolio in Q2 2026, its #68 holding.
  • Stanley Druckenmiller first reported a position in Xenon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Duquesne Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.